Revisión datos de PANITUMUMAB en función de la localización del tumor - page 13

Study 181 overview
FOLFIRI ± panitumumab in 2nd-line
Treatment of mCRC
• 1. Peeters M, et al. J Clin Oncol 2010;28:4706−13;
2. Peeters M, et al. Clin Cancer Res 2015;21:5469‒79.
• †Primary analysis.
WT RAS = WT KRAS and NRAS exons 2, 3, 4.
• Co-primary endpoint: PFS/OS1,2
• Prospective−retrospective
extended RAS analysis2
– RAS ascertainment rate: 85%
1:1
FOLFIRI (Q2W) +
panitumumab 6 mg/kg
(Q2W)
FOLFIRI (Q2W)
mCRC
(N = 1186)
WT RAS
Panitumumab +
FOLFIRI
(n = 208)
FOLFIRI
(n = 213)
Median PFS, mo†2 6.4 4.6
HR
(95% CI)
P-value
0.70
(0.54–0.91)
P = 0.007
Median OS, mo†2 16.2 13.9
HR
(95% CI)
P-value
0.81
(0.63–1.03)
P = 0.08
ORR, %†2
(95% CI)
(n = 204)
41
(34−48)
(n = 207)
10
(6−15)
AEs, %
Grade 3/4
Grade 5
(n = 207)
89.5
3.9
(n = 213)
72.5
6.1
R